| Autor: |
Yutong Chen, Tao Li, Jianing Liu, Wei Zhang, Yi Cao, Bin Hu, Hanjing Niu, Jinhua Gao, Zhongze Zhang, Kexin Yue, Guochen Bao, Jiajia Wang, Chaojie Wang, Peng Wang, Song-qiang xie, Taotao Zou, Jing Ma |
| Rok vydání: |
2023 |
| Popis: |
Regulatory T cells (Tregs) prevent autoimmunity and contribute to cancer progression. They exert contact-dependent inhibition of immune cells through the production of active transforming growth factor-β1 (TGF-β1). However, the absence of a specific surface marker makes inhibiting the production of active TGF-β1 to specifically deplete human Tregs but not other cell types a challenge. TGF-β1 in an inactive form binds to Tregs membrane protein GARP and then activates it via an unknown mechanism. Here, we demonstrate that TRAF3IP3 in the Treg lysosome is involved in this activation mechanism. Using a novel naphthalenelactam-platinum-based anticancer drug (NPt), we developed a new synergistic effect by suppressing ABCB9 and TRAF3IP3-mediated divergent lysosomal metabolic programs in tumors and human Tregs to block the production of active GARP/TGF-β1 for remodeling the tumor microenvironment. Mechanistically, NPt is stored in Treg lysosome to inhibit TRAF3IP3-meditated GARP/TGF-β1 complex activation to specifically deplete Tregs. In addition, by promoting the expression of ABCB9 in lysosome membrane, NPt inhibits SARA/p-SMAD2/3 through CHRD-induced TGF-β1 signaling pathway. In addition to expose a previously undefined divergent lysosomal metabolic program-meditated GARP/TGF-β1 complex blockade by exploring the inherent metabolic plasticity, NPt may serve as a therapeutic tool to boost unrecognized Treg-based immune responses to infection or cancer via a mechanism distinct from traditional platinum drugs and currently available immune-modulatory antibodies. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
